Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Composition : Nitrofurantoin (25mg/5ml)
Dosage Form : Suspension
Packaging Type : Bottle
Packaging : 200 ml
Price : ₹1/-
Niftafly Suspension contains Nitrofurantoin (25mg/5ml), an antibacterial medication primarily used for the treatment and prevention of urinary tract infections (UTIs) caused by susceptible organisms. Nitrofurantoin works by interfering with bacterial metabolism, inhibiting the growth of bacteria within the urinary tract. It is effective against a wide range of gram-positive and gram-negative bacteria that typically cause UTIs.
This suspension formulation is particularly beneficial for pediatric patients and those who may have difficulty swallowing tablets. The active ingredient, Nitrofurantoin, targets and kills bacteria in the bladder and urinary tract, providing relief from infection and reducing the likelihood of reinfection. It is commonly prescribed as a short-term treatment to manage acute uncomplicated UTIs or as prophylaxis for recurring infections.
Common side effects may include nausea, vomiting, loss of appetite, and diarrhea. Rare but serious side effects include pulmonary reactions and liver toxicity.
Niftafly Suspension is indicated for the treatment and prevention of urinary tract infections (UTIs) caused by susceptible bacterial strains.
This medication should be used with caution in patients with renal impairment. Always consult a healthcare provider if pregnant, breastfeeding, or experiencing any adverse effects.
Store at room temperature (15°C-30°C), away from direct light and moisture. Keep the bottle tightly closed.
Composition : Bromfenac (0.09% w/v) + Moxifloxacin (0.5% w/v)
Composition : Bromfenac (0.9mg) Eye Drops
Composition : Carboxymethylcellulose (3mg/ml) + Glycerin (10mg/ml) + n-acetylcarnosine (10mg/ml)
Composition : Dexamethasone (0.1% w/v) + Tobramycin (0.3% w/v)
Composition : Fluconazole (0.3% w/v)
Composition : Gatifloxacin (0.3% w/v)
Composition : Ketorolac (0.4% w/v) + Olopatadine (0.1% w/v)
Composition : Ketorolac (0.5% w/v)
Composition : Ketorolac (5% w/v) + Moxifloxacin (0.5% w/v)
Composition : Loteprednol etabonate (0.5% w/v)
Strategic Advisory
Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.
View Professional Profile
Start Your Journey
Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our Successful network today.
Quick Navigation
1500+ Products
Our Divisions
All Therapeutics
Disclaimer: Pharma Insights are based on operational standards as of March 2026. All territories are subject to availability and Revised Schedule M compliance.